Appearance of anaphylactic shock after long-term intravenous itraconazole treatment

Annals of Pharmacotherapy

Volumn 43, Issue 3, 2009, Pages 537-541

  Chen, Jie ^a   Song, Xianmin ^a   Yang, Peng ^a   Wang, Jianmin ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Anaphylactic shock; Itraconazole; Steroid

Indexed keywords

AMPHOTERICIN B; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ASPARAGINASE; CYTARABINE; DEXAMETHASONE; DOPAMINE; GRANULOCYTE COLONY STIMULATING FACTOR; ITRACONAZOLE; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; NAVELBINE; PANIPENEM; STEROID; VORICONAZOLE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ANAMNESIS; ANAPHYLACTIC SHOCK; ARTICLE; CASE REPORT; CLINICAL FEATURE; COUGHING; DISEASE COURSE; DISEASE SEVERITY; DRUG ANTAGONISM; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; FEBRILE NEUTROPENIA; FEMALE; GRANULOCYTOPENIA; HEART PALPITATION; HUMAN; HYPOTENSION; HYPOXEMIA; LABORATORY TEST; LONG TERM CARE; LUNG INFECTION; MYCOSIS; NAUSEA; OXYGEN THERAPY; PETECHIA; PHYSICAL EXAMINATION; PRIORITY JOURNAL; TACHYCARDIA; TREATMENT OUTCOME; VOMITING;

ADULT; ANAPHYLAXIS; ANOXIA; ANTIFUNGAL AGENTS; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; HYPOTENSION; INJECTIONS, INTRAVENOUS; ITRACONAZOLE; LUNG DISEASES, FUNGAL;

EID: 62949230395     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1L343     Document Type: Article

References (17)

1. Kauffman CA. Fungal infections. Proc Am Thorac Soc 2006;3:35-40. DOI 10.1513/pats.200510-110JH
2. Abdel-Rahman SM, Jacobs RF, Massarella J, et al. Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents. Antimicrob Agents Chemother 2007;51:2668-73. DOI 10.1128/AAC.00297-07
3. Schuler U, Bammer S, Aulitzky WE, et al. Safety and efficacy of itraconazole compared to amphotericin B as empirical antifungal therapy for neutropenic fever in patients with haematological malignancy. Onkologie 2007;30:185-91. DOI 10.1159/000100055
4. Gupta AK, Chwetzoff E, Del Rosso J, Baran R. Hepatic safety of itraconazole. J Cutan Med Surg 2002;6:210-3. DOI 10.1007/S10227-001-0048-3
5. Wang A, Zhang Y, He L, et al. Clinical study on the efficacy and safety of intravenous itraconazole infusion for the treatment of invasive fungal infection in China. Jpn J Infect Dis 2006;59:370-6.
6. Okamoto J, Fukunami M, Kioka H. Frequent premature ventricular contractions induced by itraconazole. Cire J 2007:71:1323-5. DOI 10.1253/circj.71.1323
7. Talwalkar JA, Soetikno RE, Carr-Locke DL, Berg CL. Severe cholestasis related to itraconazole for the treatment of onychomycosis. Am J Gastroenterol 1999;94:3632-3.
8. Langers AM. Jonkers GJ. Pancreatitis ascribed to the use of itraconazole. Ned Tijdschr Geneeskd 2001 ; 145:1127-8.
9. Tuccori M, Bresci F, Guidi B, Blandizzi C, Del Tacca M, Di Paolo M. Fatal hepatitis after long-term pulse itraconazole treatment for onychomycosis. Ann Pharmacother. 2008; 42:1112-7. Epub 3 June 2008. DOI 10.1345/aph.lL051
10. Mowat E, Butcher J, Lang S, Williams C, Ramage G, Development of a simple model for studying the effects of antifungal agents on multicellular communities of Aspergillus fumigatus. J Med Microbiol 2007;56: 1205-12. DOI 10.1099/jmm.0.47247-0
11. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
12. Posadas SJ, Pichler WJ. Delayed drug hypersensitivity reactions- new concepts. Clin Exp Allergy 2007;37:989-99. DOI 10.1111/j.1365-2222.2007.02742.x
13. Liu P-Y, Lee C-H, Lin L-J, Chen J-H. Refractory anaphylactic shock associated with ketoconazole treatment. Ann Pharmacother 2005;39:547- 50. Epub 8 Feb 2005. DOI 10.1345/aph.lE465
14. Jalava KM, Olkkola KT, Neuvonen PJ. Itraconazole greatly increases plasma concentrations and effects of felodipine. Clin Pharmacol Ther 1997;61:410-5. DOI 10.1016/S0009-9236(97)90191-0
15. El-Chennawi FA, Al-Tonbary YA, Mossad YM, Ahmed MA. Immune reconstitution during maintenance therapy in children with acute lymphoblastic leukemia, relation to co-existing infection. Hematology 2008; 13:203-9.
16. Schäfer-Korting M. Pharmacokinetic optimisation of oral antifungal therapy. Clin Pharmacokinet 1993;25:329-41.
17. Mouton JW, van Peer A, de Beule K, Van Vliet A, Donnelly JP, Soons P A. Pharmacokinetics of itraconazole and hydroxy itraconazole in healthy subjects after single and multiple doses of a novel formulation. Antimicrob Agents Chemother 2006;50:4096-102. DOI 10.1128/AAC.00630-06.